Kinase News and Research

RSS

CML survey reveals patient TKI adherence, disease anxiety

Survey results suggest that chronic myeloid leukaemia patients using tyrosine kinase inhibitor therapy have good adherence to treatment but might benefit from counselling regarding their illness.

17 Aug 2015

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

Allogeneic haematopoietic stem cell transplantation can be considered for chronic- and accelerated-phase chronic myeloid leukaemia patients with prior exposure to second-generation tyrosine kinase inhibitors, say Polish researchers.

17 Aug 2015

TKI outcomes ‘unfavourable’ in young CML patients

Adolescent and young adult patients with chronic myeloid leukaemia may have an unfavourable outcome on tyrosine kinase inhibitor therapy compared with their older counterparts, suggests a study of Japanese patients.

17 Aug 2015

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

14 Aug 2015

CML survey reveals patient TKI adherence, disease anxiety

Survey results suggest that chronic myeloid leukaemia patients using tyrosine kinase inhibitor therapy have good adherence to treatment but might benefit from counselling regarding their illness.

14 Aug 2015

TKI outcomes ‘unfavourable’ in young CML patients

14 Aug 2015

3D protein structure reveals new drug targets for cancer, neurodegenerative diseases

Protein Kinase C (PKC) is a family of enzymes that controls the activity of other proteins in a cell by attaching chemical tags. That simple act helps determine cell survival or death.

14 Aug 2015

Researchers elucidate mechanism that induces skeletal muscle atrophy in patients with congestive heart failure

It is a paradox: Patients with advanced congestive heart failure lose skeletal muscle mass, but their heart muscles become enlarged to provide the body with an adequate supply of blood and thus with oxygen. It has long been known that the protein angiotensin II plays a villainous role in this process, but the exact mechanism has remained unclear.

12 Aug 2015

Barbara Ann Karmanos Cancer Institute, Wayne State University participate in NCI MATCH Trial

The Barbara Ann Karmanos Cancer Institute, in partnership with Wayne State University School of Medicine, is one of the lead academic centers participating in the National Cancer Institute's (NCI) MATCH (Molecular Analysis for Therapy Choice) Trial in the United States, set to begin in the next few weeks.

11 Aug 2015

Study reveals that miR-7 suppresses gastric cancer by inhibiting key signaling pathway

A study in The Journal of Cell Biology reveals that the microRNA miR-7 suppresses gastric (stomach) cancer by inhibiting a key signaling pathway, and that this protective mechanism is compromised by the cancer-causing bacterium H. pylori. Finding drugs capable of inducing miR-7 could therefore prove to be an effective treatment against the progression of gastric cancer.

11 Aug 2015

Novel treatment target found for RV failure in PAH

Researchers have identified a molecular pathway by which downregulation of microRNA-126 contributes to right ventricular failure in patients with pulmonary arterial hypertension.

10 Aug 2015

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.

7 Aug 2015

UNC researchers show how a genetic mutation disables molecular switch and causes autism

Last December, researchers identified more than 1,000 gene mutations in individuals with autism, but how these mutations increased risk for autism was unclear. Now, UNC School of Medicine researchers are the first to show how one of these mutations disables a molecular switch in one of these genes and causes autism.

7 Aug 2015

Genetic test may help identify better treatment option for HER2-positive breast cancer patients

A genetic test for PIK3CA mutations may help to identify patients with HER2-positive breast cancer who are less likely to benefit from combination anti-HER2 therapy, according to a study published in The Oncologist on August 5, 2015.

6 Aug 2015

Hedgehog blockade promising in myeloid malignancies

Phase I trial results published in The Lancet Haematology show that the hedgehog signalling pathway antagonist PF-04449913 is tolerable and has activity in patients with haematological cancers.

5 Aug 2015

MD Anderson scientists reveal role of metabolic enzyme fumarase in DNA repair

DNA double-strand breaks (DSBs) are the worst possible form of genetic malfunction that can cause cancer and resistance to therapy. New information published this week reveals more about why this occurs and how these breaks can be repaired.

4 Aug 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

RNA-binding protein ROQUIN regulates response to DNA damage

Messenger (mRNA) molecules are a key component of protein biosynthesis. They are first transcribed as a "working copy" of the DNA and then translated into protein molecules.

3 Aug 2015

Understanding the workings of error correction mechanism in cell division

Cell biologists led by Thomas Maresca at the University of Massachusetts Amherst, with collaborators elsewhere, report an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.

30 Jul 2015

New tool combines drugs to target kinase dependency in cancer

Targeted therapies attack a cancer's genetic sensitivities. However, it can be difficult to discover the genetics driving a patient's cancer, and the effects of drugs designed to target a genetic abnormality often go beyond their intended target alone. The result is threefold: sometimes a drug is prescribed to treat a target that proves to be irrelevant to the disease, sometimes an existing drug could be used to treat a cancer for which there is no approved targeted therapy, and sometimes a combination of targeted treatments could be used to simultaneously silence more than one genetic cause of a patient's cancer.

29 Jul 2015

Kinase News and Research

CML survey reveals patient TKI adherence, disease anxiety

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

TKI outcomes ‘unfavourable’ in young CML patients

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

CML survey reveals patient TKI adherence, disease anxiety

TKI outcomes ‘unfavourable’ in young CML patients

3D protein structure reveals new drug targets for cancer, neurodegenerative diseases

Researchers elucidate mechanism that induces skeletal muscle atrophy in patients with congestive heart failure

Barbara Ann Karmanos Cancer Institute, Wayne State University participate in NCI MATCH Trial

Study reveals that miR-7 suppresses gastric cancer by inhibiting key signaling pathway

Novel treatment target found for RV failure in PAH

Vascular side effects prevent first-line ponatinib use in chronic phase CML

UNC researchers show how a genetic mutation disables molecular switch and causes autism

Genetic test may help identify better treatment option for HER2-positive breast cancer patients

Hedgehog blockade promising in myeloid malignancies

MD Anderson scientists reveal role of metabolic enzyme fumarase in DNA repair

Array Biopharma reports strong fourth quarter and full year 2015 financial results

RNA-binding protein ROQUIN regulates response to DNA damage

Understanding the workings of error correction mechanism in cell division

New tool combines drugs to target kinase dependency in cancer

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News